milrinone has been researched along with Blood Pressure, Low in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of milrinone on induced hypotension during spinal surgery in elderly patients." | 9.19 | The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial. ( Hwang, W; Kim, E, 2014) |
| " We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine." | 9.12 | Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. ( Bahk, JH; Choi, JY; Jeon, Y; Kim, CS; Lim, YJ; Ryu, JH; Yoon, SZ, 2006) |
| "Hypotension is an adverse event that may be related to systemic exposure of milrinone; however, the true exposure-safety relationship is unknown." | 8.12 | The relationship between simulated milrinone exposure and hypotension in children. ( Balevic, SJ; Cohen-Wolkowiez, M; Commander, SJ; Gonzalez, D; Hornik, CP; Kumar, KR; Spears, T; Zimmerman, KO, 2022) |
| " Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol." | 7.70 | Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998) |
| "Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension." | 7.70 | Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. ( Chen, J; Cullinane, S; Gold, JA; Landry, DW; Oliver, JA; Oz, MC, 2000) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 7.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 6.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Milrinone is a phosphodiesterase type III inhibitor with positive inotropic and vasodilatory effects." | 5.31 | Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis. ( Ewald, G; Mindel, G; Saab, G; Vijayan, A, 2002) |
| "To determine the effect of milrinone on induced hypotension during spinal surgery in elderly patients." | 5.19 | The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial. ( Hwang, W; Kim, E, 2014) |
| " We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine." | 5.12 | Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. ( Bahk, JH; Choi, JY; Jeon, Y; Kim, CS; Lim, YJ; Ryu, JH; Yoon, SZ, 2006) |
| "Hypotension is an adverse event that may be related to systemic exposure of milrinone; however, the true exposure-safety relationship is unknown." | 4.12 | The relationship between simulated milrinone exposure and hypotension in children. ( Balevic, SJ; Cohen-Wolkowiez, M; Commander, SJ; Gonzalez, D; Hornik, CP; Kumar, KR; Spears, T; Zimmerman, KO, 2022) |
| "Population pharmacokinetic modeling and simulations suggest a slow loading dose followed by maintenance infusion to reach therapeutic milrinone plasma concentrations within the timeframe of the postligation cardiac syndrome." | 3.91 | Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ( Hallik, M; Ilmoja, ML; Jalas, T; Kipper, K; Metsvaht, T; Raidmäe, M; Standing, JF; Starkopf, J; Takkis, K; Tasa, T; Uibo, K; Veigure, R, 2019) |
| " Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol." | 3.70 | Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998) |
| "Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension." | 3.70 | Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. ( Chen, J; Cullinane, S; Gold, JA; Landry, DW; Oliver, JA; Oz, MC, 2000) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 3.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| "Milrinone was associated with a higher incidence of sinus bradycardia (D = 2%, M = 13%; p < 0." | 2.70 | Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. ( Feneck, RO; Oduro-Dominah, A; Sherry, KM; Withington, PS, 2001) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 2.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Milrinone has been suggested as a possible first-line therapy for preterm neonates to prevent postligation cardiac syndrome (PLCS) through decreasing systemic vascular resistance and increasing cardiac contractility." | 1.46 | Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. ( Hallik, M; Metsvaht, T; Starkopf, J; Tasa, T, 2017) |
| "Hypotension is a common problem in neonates with complex underlying pathophysiology." | 1.46 | Management of Neonatal Hypotension. ( Kalish, BT, 2017) |
| " We identified adverse events (AEs) during milrinone exposure." | 1.42 | Safety of milrinone use in neonatal intensive care units. ( Brian Smith, P; Clark, RH; Hornik, CP; McHutchison, K; Raman, SR; Samiee-Zafarghandy, S; van den Anker, JN, 2015) |
| "The echocardiographic presence of mild aortic regurgitation combined with left ventricular hypocontractility in a structurally normal heart should alert the physician to the presence of underlying hypertension." | 1.39 | Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues. ( Allegaert, K; Brown, S; Cools, B; Eyskens, B; Gewillig, M; Heying, R; Levtchenko, E; Louw, J; Smits, A; Thewissen, L, 2013) |
| " Beta-blocker dosages were titrated, and three patients achieved the target beta-blocker dosage established for stage A-C heart failure." | 1.34 | Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. ( Earl, GL; Fitzpatrick, JM; Narula, J; Verbos-Kazanas, MA, 2007) |
| "Milrinone is a phosphodiesterase type III inhibitor with positive inotropic and vasodilatory effects." | 1.31 | Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis. ( Ewald, G; Mindel, G; Saab, G; Vijayan, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.76) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Phad, N | 1 |
| de Waal, K | 1 |
| Commander, SJ | 1 |
| Gonzalez, D | 1 |
| Kumar, KR | 1 |
| Spears, T | 1 |
| Cohen-Wolkowiez, M | 1 |
| Zimmerman, KO | 1 |
| Balevic, SJ | 1 |
| Hornik, CP | 2 |
| Elhassan, A | 1 |
| Essandoh, M | 1 |
| Hallik, M | 2 |
| Ilmoja, ML | 1 |
| Tasa, T | 2 |
| Standing, JF | 1 |
| Takkis, K | 1 |
| Veigure, R | 1 |
| Kipper, K | 1 |
| Jalas, T | 1 |
| Raidmäe, M | 1 |
| Uibo, K | 1 |
| Starkopf, J | 2 |
| Metsvaht, T | 2 |
| Dempsey, E | 1 |
| Rabe, H | 1 |
| Qin, H | 1 |
| Jiang, W | 1 |
| EL-Khuffash, A | 1 |
| McNamara, PJ | 1 |
| Lapointe, A | 1 |
| Jain, A | 1 |
| Louw, J | 1 |
| Brown, S | 1 |
| Thewissen, L | 1 |
| Smits, A | 1 |
| Eyskens, B | 1 |
| Heying, R | 1 |
| Cools, B | 1 |
| Levtchenko, E | 1 |
| Allegaert, K | 1 |
| Gewillig, M | 1 |
| Hwang, W | 1 |
| Kim, E | 1 |
| Samiee-Zafarghandy, S | 1 |
| Raman, SR | 1 |
| van den Anker, JN | 1 |
| McHutchison, K | 1 |
| Clark, RH | 1 |
| Brian Smith, P | 1 |
| Meyer, S | 1 |
| Tagawa, M | 1 |
| Nanba, H | 1 |
| Suzuki, H | 1 |
| Nakamura, Y | 1 |
| Uchiyama, H | 1 |
| Ochiai, S | 1 |
| Terunuma, M | 1 |
| Yahata, K | 1 |
| Minamino, T | 1 |
| Kalish, BT | 1 |
| Cuevas Valenzuela, P | 1 |
| Rufino Ruiz, J | 1 |
| Palacios Blanco, E | 1 |
| Toth-Heyn, P | 1 |
| Cataldi, L | 1 |
| Saab, G | 1 |
| Mindel, G | 1 |
| Ewald, G | 1 |
| Vijayan, A | 1 |
| Smull, DL | 1 |
| Jorde, UP | 1 |
| Liet, JM | 1 |
| Jacqueline, C | 1 |
| Orsonneau, JL | 1 |
| Gras-Leguen, C | 1 |
| Potel, G | 1 |
| Rozé, JC | 1 |
| Seri, I | 2 |
| Noori, S | 1 |
| Osborn, DA | 1 |
| Johnston, AM | 1 |
| Carr, B | 1 |
| Jeon, Y | 1 |
| Ryu, JH | 1 |
| Lim, YJ | 1 |
| Kim, CS | 1 |
| Bahk, JH | 1 |
| Yoon, SZ | 1 |
| Choi, JY | 1 |
| Lange, M | 1 |
| Van Aken, H | 1 |
| Westphal, M | 1 |
| Mayr, V | 1 |
| Luckner, G | 1 |
| Jochberger, S | 1 |
| Wenzel, V | 1 |
| Ulmer, H | 1 |
| Pajk, W | 1 |
| Knotzer, H | 1 |
| Friesenecker, B | 1 |
| Lindner, K | 1 |
| Hasibeder, W | 1 |
| Dünser, M | 1 |
| Earl, GL | 1 |
| Verbos-Kazanas, MA | 1 |
| Fitzpatrick, JM | 1 |
| Narula, J | 1 |
| Shubert, J | 1 |
| Mancano, MA | 1 |
| Pina, IL | 1 |
| Milfred, SK | 1 |
| Mehra, MR | 1 |
| Ventura, HO | 1 |
| Kapoor, C | 1 |
| Stapleton, DD | 1 |
| Zimmerman, D | 1 |
| Smart, FW | 1 |
| Alhashemi, JA | 1 |
| Hooper, J | 1 |
| Orime, Y | 1 |
| Shiono, M | 1 |
| Hata, H | 1 |
| Yagi, S | 1 |
| Tsukamoto, S | 1 |
| Okumura, H | 1 |
| Kimura, S | 1 |
| Hata, M | 1 |
| Sezai, A | 1 |
| Obana, M | 1 |
| Sezai, Y | 1 |
| Gold, JA | 1 |
| Cullinane, S | 2 |
| Chen, J | 2 |
| Oz, MC | 2 |
| Oliver, JA | 2 |
| Landry, DW | 2 |
| Gold, J | 1 |
| Seo, S | 1 |
| Feneck, RO | 1 |
| Sherry, KM | 1 |
| Withington, PS | 1 |
| Oduro-Dominah, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension[NCT04599816] | 45 participants (Actual) | Interventional | 2020-10-17 | Completed | |||
| Comparison of Intravenous Levosimendan and Inhalational Milrinone in High Risk Cardiac Patients With Pulmonary Hypertension[NCT04718350] | 40 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for milrinone and Blood Pressure, Low
| Article | Year |
|---|---|
What Inotrope and Why?
Topics: Cardiac Output; Cardiotonic Agents; Dobutamine; Dopamine; Echocardiography; Epinephrine; Heart; Huma | 2020 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defect | 2019 |
Vasoactive compounds in the neonatal period.
Topics: Adrenal Cortex Hormones; Cardiovascular System; Catecholamines; Humans; Hydrazones; Hypotension; Inf | 2012 |
Diagnosis and treatment of neonatal hypotension outside the transitional period.
Topics: Adrenal Insufficiency; Dobutamine; Dopamine; Ductus Arteriosus, Patent; Humans; Hypotension; Infant, | 2005 |
Diagnosis and treatment of preterm transitional circulatory compromise.
Topics: Adrenal Cortex Hormones; Blood Circulation; Blood Pressure; Cardiac Output, Low; Dobutamine; Dopamin | 2005 |
4 trials available for milrinone and Blood Pressure, Low
| Article | Year |
|---|---|
The effect of milrinone on induced hypotension in elderly patients during spinal surgery: a randomized controlled trial.
Topics: Aged; Blood Loss, Surgical; Double-Blind Method; Elective Surgical Procedures; Female; Hemodynamics; | 2014 |
Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.
Topics: Aged; Coronary Artery Bypass, Off-Pump; Double-Blind Method; Female; Humans; Hypotension; Intraopera | 2006 |
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Drug Administration Schedule; Drug Ther | 1997 |
Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery.
Topics: Adrenergic beta-Agonists; Blood Gas Analysis; Cardiac Output, Low; Cardiac Surgical Procedures; Dobu | 2001 |
25 other studies available for milrinone and Blood Pressure, Low
| Article | Year |
|---|---|
The relationship between simulated milrinone exposure and hypotension in children.
Topics: Cardiotonic Agents; Child; Hemodynamics; Humans; Hypotension; Milrinone | 2022 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Inhaled Levosimendan for Pulmonary Hypertension Treatment During Cardiac Surgery: A Novel Application to Avoid Systemic Hypotension.
Topics: Double-Blind Method; Humans; Hypertension, Pulmonary; Hypotension; Milrinone; Mitral Valve; Pilot Pr | 2019 |
Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants.
Topics: Cardiotonic Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Hypotension; Infant | 2019 |
Myocarditis in fulminant meningococcemia.
Topics: Adult; Anti-Bacterial Agents; Cardiotonic Agents; Ceftriaxone; Cerebrospinal Fluid; Confusion; Femal | 2019 |
Adrenal function in preterm infants undergoing patent ductus arteriosus ligation.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Cardiotonic Agents; Cohort Studies; Ductus Arter | 2013 |
Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues.
Topics: Acute Disease; Antihypertensive Agents; Aortic Valve Insufficiency; Arterial Pressure; Body Weight; | 2013 |
Safety of milrinone use in neonatal intensive care units.
Topics: Cardiotonic Agents; Female; Humans; Hypotension; Infant, Newborn; Infant, Premature; Intensive Care | 2015 |
Use of milrinone in neonatal intensive care medicine.
Topics: Cardiotonic Agents; Female; Humans; Hypotension; Intensive Care Units, Neonatal; Male; Milrinone; Th | 2015 |
Ventricular Rhythm and Hypotension in a Patient with Pheochromocytoma-induced Myocardial Damage and Reverse Takotsubo Cardiomyopathy.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Adult; Biomarkers; Cardiac Cat | 2015 |
Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion.
Topics: Cardiac Output; Cardiotonic Agents; Ductus Arteriosus, Patent; Estonia; Female; Gestational Age; Hum | 2017 |
Management of Neonatal Hypotension.
Topics: Blood Pressure; Cardiotonic Agents; Dobutamine; Dopamine; Ductus Arteriosus, Patent; Humans; Hypoten | 2017 |
[Mulibrey syndrome: anesthetic management].
Topics: Abnormalities, Multiple; Anesthesia, Inhalation; Ascites; Child; Comorbidity; Dopamine; Drainage; Fe | 2010 |
Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis.
Topics: Acute Kidney Injury; Adrenergic beta-Agonists; Amyloidosis; Cardiotonic Agents; Dobutamine; Drug Adm | 2002 |
Concomitant use of nesiritide and milrinone in decompensated congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Drug Synergism; Drug Therapy, Combination; Female; | 2005 |
The effects of milrinone on hemodynamics in an experimental septic shock model.
Topics: Animals; Dilatation, Pathologic; Disease Models, Animal; Female; Hemodynamics; Hypotension; Milrinon | 2005 |
Community-acquired bacterial meningitis.
Topics: Catheterization, Swan-Ganz; Community-Acquired Infections; Humans; Hypotension; Meningitis, Bacteria | 2006 |
Is vasopressin really superior to norepinephrine in reversing milrinone-induced vasodilation?
Topics: Coronary Artery Bypass; Humans; Hypotension; Milrinone; Norepinephrine; Vasoconstrictor Agents; Vaso | 2006 |
Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest.
Topics: Aged; Arginine Vasopressin; Bilirubin; Blood Pressure; Epinephrine; Female; Heart Arrest; Humans; Hy | 2007 |
Cardiovascular support in the preterm: treatments in search of indications.
Topics: Cardiac Output, Low; Cardiotonic Agents; Cardiovascular System; Dopamine; Female; Humans; Hypotensio | 2007 |
Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Cardiac Output, | 2007 |
Criteria for use of intravenous milrinone in adult inpatients.
Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Humans; Hypotension; Infusio | 1995 |
Treatment of milrinone-associated tachycardia with beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia, Epidural; Anesthesia, General; Anti-Arrhythmia Agents | 1998 |
Effects of phosphodiesterase inhibitors after coronary artery bypass grafting.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Dobutamine; Dopamine; Female; Hemodynamics; Humans | 1999 |
Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Coronary Artery Bypass; Fatal Outcome; Female; Heart Va | 2000 |
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 3; H | 2000 |